Endomorphin-2 (H-Tyr-Pro-Phe-Phe-NH 2 ) and [Dmt 1 ]EM-2 (Dmt = 2',6'-dimethyl-
Introduction
Endomorphin-1 (EM-1: H-Tyr-Pro-Trp-Phe-NH 2 ) and endomorphin-2 (EM-2: H-Tyr-ProPhe-Phe-NH 2 ) are endogenous opioid peptides with remarkably high selectivity for μ-opioid receptors. 1 Since the endomorphins express pharmacological properties similar to morphine and are thought to inhibit pain without its undesirable side effects, 2,3 extensive studies have been performed in order to clarify their pharmacological characteristics, 4-9 bioactive conformation, 10-14 and to improve biological activity in vitro and in vivo by chemical modificaton. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] The aromatic amino acid residue in position 3 is the defining structural determinant between EM-1 (Trp 3 ) and EM-2 (Phe 3 ). 1, 26 Moreover, extensive studies previously indicated that Dmt (2',6'-dimethyl-L-tyrosine) in lieu of the N-terminal Tyr dramatically enhanced receptor affinity and bioactivity of numerous opioid agonists and antagonists, 27,28 and data on endomorphin-2 analogues modified at position 1 with tyrosine analogues alkylated on the tyramine ring improved in vitro biological parameters. 29 Similarly, an alkylated Phe analogue, 2',6'-dimethylphenylalanine (Dmp), was an effective surrogate for phenylalanine in several opioid peptides, such as dynorphin A, 30 [Leu 5 ]enkephalin, 31 dermorphin, deltorphin II, 32 YrFB (H-Tyr-D-Arg-Phe-βAla-NH 2 ), 33 and endomorphin-2. 34 Furthermore, the replacement of Tyr 1 by Dmp in deltorphin II and enkephalin also yielded analogues which were surprisingly nearly as effective as the parental peptides, 35 suggesting that alkylation of the aromatic ring enhances hydrophobicity, stability and/or limits rotational freedom in its solution conformation.
Rationale
It is well known that a subtle change in both the hydrophobicity and spatial conformation of an opioid ligand contributes not only to a modification of its overall activity profile (receptor affinity, bioactivity) 30,32,34,35 and physicochemical properties (stability, conformation), 14, 18,21,31 but also to its biological efficacy (in vitro, in vivo) as an antinociceptive agent 27, 28,36 with an enhanced ability to transit the blood-brain barrier. 36,37 In this regard, N,Nalkylation converted a potent δ-opioid antagonist into an inverse agonist, 38 and led to the appearance of elevated μ-opioid receptor affinity and increased δ-antagonism among numerous analogues of the Dmt-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) pharmacophoric compounds. 39 On the other hand, the acquisition of a greater degree of hydrophobicity through alkylation of the tyramine ring of Tyr 1 permitted further differentiation of the biological properties between the structurally related endomorphin-1 and -2 molecules. 29, 36 In light of ability of the dialkylated derivative of phenylalanine (Dmp) to substitute for Tyr 1 in deltorphin II 35 and for Phe in other opioids, 30-35 the importance of the residue in the third position of the endomorphins, which is known to affect their receptor selectivity and bioactivity, 1-4,6,7 should be amenable to alterations in the hydrophobic millieu of the aromatic moiety of Phe. A change in overall change in conformation or reduced freedom of rotation imparted by the alkyl substituents should provide a gauge on the potential effect of the substitution on receptor interaction and functional bioactivity parameters (Figure 1 ). Furthermore, in light of the importance of μ-opioid receptors in modulating pain, appetite and alcohol induced elevation of spontaneous inhibition of postsynaptic currents (IPSC) 40 and the involvement of δ-opioid receptors in ameliorating the morphine tolerance and dependence due to the μ-opioid system, 41 this study focused exclusively on these two important and interrelated opioid systems; furthermore, as our data reveal (infra vide), these EM-2 analogues are essentially devoid of activity toward κ-opioid receptors. In fact, our data reveal that the combination of Dmt 1 and an alkylated Phe 3 substitution provides unique evidence for the change in the bioactivities of several analogues, including identification of potent bifunctional μ-opioid receptor agonists containing δ-antagonist or δ-agonist properties.
Chemistry
Dmt was synthesized by following the method described by Dygos et al. 42 The Phe analogues ( Figure 1 ) containing 2'-methyl (Mmp) (R 2 ), 3',5'-dimethyl ( 3,5 Dmp) (R 3 ,R 5 ), 2',6'-dimethyl (Dmp) (R 2 ,R 6 ), 2',4',6'-trimethyl (Tmp) (R 2 ,R 4 ,R 6 ), 2'-ethyl-6'-methyl (Emp) (R 2 ,R 6 ) and 2'-isopropyl-6'-methyl (Imp) (R 2 ,R 6 ) were prepared as reported through [Rh(1,5-COD)(R,R-DIPAMP)]BF 4 , [(R,R)-(−)-1,2-Bis-[(o-methoxyphenyl)(phenyl)phosphino]ethane(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate] mediated asymmetric catalytic hydrogenation of corresponding acetamidoacrylate. 43 Boc(tert-butyloxycarbonyl)-Tyr-Pro-OH 44 and Boc-Dmt-Pro-OH 40 were prepared as reported. Tyr/Dmt-Pro-Xaa-Phe-NH 2 (Xaa = Mmp, 3, 5 Dmp, Dmp, Dmt, Tmp, Emp, Imp) was formed by segment condensation method in solution. Briefly, after deprotection of Boc-Xaa-Phe-NH 2 with HCl/dioxane, the resulting H-Xaa-Phe-NH 2 was condensed with Boc-Tyr/Dmt-Pro-OH using PyBop (benzotriazol-1-yloxytrispyrrolidinophosphonium hexafluorphosphate) as the coupling reagent. The final Boc protecting group was removed with HCl/dioxane in the presence of anisole, and the resulting peptide was purified by semi-preparative RP(reversed phase)-HPLC.
The identification and purity of the final compounds and their intermediates were verified using MS, NMR, analytical HPLC, and elemental analysis. Some analytical data of the final compounds are summarized in Table 1 . The final compounds exhibiting greater than 98% purity were used for all biological assays. Supporting Information provides detailed elemental analyses of all the compounds.
Results and Discussion

Opioid Receptor Affinity
Improved affinities for μ-opioid receptors were observed in the [Xaa 3 ]EM-2 compounds (2, 4, 6-8) compared to the parent peptide (1), except 3 and 5 that exhibited weaker affinities ( Table 2 ). Introduction of a single methyl group at the 2'-position of Phe (2) enhanced μ-opioid receptor affinity 6-fold; a second methyl group at the 6'-position (4) induced a further 5-fold increase. Sterically bulky groups, such as third methyl group at the 4'-position (6) , an ethyl (7) or isopropyl (8) at the 6'-position ( Figure 1 ) reduced receptor affinity by a factor of 10 relative to [Dmp 3 ]EM-2 (4), which exhibits the highest μ-selectivity of any known μ-opioid agonist; 1,34 nonetheless, the μ-affinities of 6, 7 and 8 were still 3-fold greater than the naturally occurring EM-2 (1) ( Table 2 ). Another dimethylated Phe derivative, [ 3, 5 Dmp 3 ]EM-2 (3), displayed the lowest μ-opioid receptor affinity of all the analogues (Table 2) , being 141-fold lower than [Dmp 3 ]EM-2 (4) and ca. 5-fold less than 1, suggesting that the position of the alkyl groups on the Phe 3 aromatic ring was a critical factor for receptor affinity.
Among the [Dmt 1 ,Xaa 3 ]EM-2 ligands (1'-8') ( Table 2) , alkylated Phe 3 analogues essentially enhanced the affinities for both μ-and δ-opioid receptors, although minor discrepancies in μ-opioid receptor affinity were noted for 6', 7' and 8' in comparison to the [Xaa 3 ]EM-2 substances. Although they displayed improved δ-opioid receptor affinity, μ-opioid selectivity remained. As published previously, the presence of Dmt 1 in opioids enhanced δ-opioid receptor affinity by orders of magnitude; 27-29,45 however, with μ-opioid selective agonists, a Nterminal Dmt residue enhanced affinity to δ-sites to a greater extent than found with the prototype δ-opioid antagonists containing the Dmt-Tic pharmacophore, 45 as seen by the 634-fold increase in δ-opioid affinity in 4' relative to 4 with the concomitant loss of μ selectivity by three orders of magnitude (Table 2 ). In these Dmt-derivatives, the highest μ-opioid selectivity occurred with [Dmt 1,3 ]EM-2 (5') (K i δ /K i μ = 878), which was less (37-fold) than the most selective [Xaa 3 ]EM-2 compound (4), but nearly 3-fold greater than 1' ( Table 2) . One analogue of considerable interest is Tmp 3 (6'): with a 44-fold greater interaction than Dmt 3 (5') toward δ-opioid receptors, the data suggest that the hydrogen donor capability of the hydroxyl group of Dmt is apparently less effective in affecting receptor interaction when situated within the peptide than the hydrophobicity of the 4' methyl group; i.e., the hydroxyl group may contribute a negative influence as an internal residue supporting the original study on the endomorphins. 1
As seen in Table 2 , κ-opioid receptor affinities for the Dmt-derivatives (1'-8') and parental compounds (1,4) were quite weak relative to the interaction of these peptides to both μ-and δ-opioid receptors, although the control U-69593 demonstrated good affinity (1.04 ± 0.45 nM).
Owing to the lack of high κ-opioid affinity, none of the analogues were investigated for their functional bioactivity.
Functional Bioactivity
The functional bioactivities (Table 3 ) of the [Xaa 3 ]EM-2 analogues exhibited considerable variation in μ-agonism relative to EM-2 (1): analogues 2, 6, 7 and 8 were 2-to 5-fold more active, while 3 and 5 were inactive. The increase in hydrophobicity and positioning of the methyl groups on Phe 3 changed μ-agonism relative to EM-2 (1); i.e., while alkylation at the 3' and 5' positions of Phe 3 inactivated the molecule (3), substitutions at positions 2' and 6' were very well tolerated (4) producing dual μ-/δ-agonism. 34 Moreover, trimethylation (6) yielded a highly selective μ-agonist.
The [Dmt 1 ,Xaa 3 ]EM-2 analogues (Table 3) generally doubled μ-opioid bioactivities (2', 4'), remained essentially unchanged (5', 6', 7', 8') or lost bioactivity (3') relative to 1'. 29 Compound 3' was an anomaly; the biopotency of this analogue correlated with μ-opioid receptor affinity, suggesting that the methyl groups at positions 3' and 5' (3, 3') presented an unfavorable conformation for activation of the μ-opioid receptor, whereas the dimethyl alkylation at positions 2' and 6' in Phe 3 (4') (and 4) 34 was permitted. This was equally true for the trimethyl-(6'), ethylmethyl-(7') and isopropylmethyl-Phe 3 (8') In terms of the δ-functional bioactivities, the majority of the ligands failed to elicit substantial δ-agonism except 7' and to a lesser extent both 8' (10-fold loss) and 2 (30- 
Conclusion
This study demonstrated that alkylated Phe 3 residues incorporated into the third position of EM-2 act as effective amino acid surrogates, in particular the [Dmt 1 ,Xaa 3 ]EM-2 analogues, which exhibited significantly higher affinity for both μ-and δ-opioid receptors, yet retained μ-opioid bioactivity. The lack of interaction of the analogues with κ-opioid receptors revealed that these compounds maintained the selectivity of endomorphin for μ-opioid receptors. The most intriguing observation was the unique appearance of δ-antagonism in the endomorphins, which normally lack interaction with δ-opioid receptors and have high μ-opioid receptor selectivity and prominent μ-opioid agonism. 1 These bifunctional molecules are targets in the design of a new antinociceptive opioids that could potentially alleviate acute or chronic pain with low physical dependence and tolerance, 41 especially due to the acquisition of δ-opioid antagonism. Pharmacological and biochemical evidence further reveal that μ-and δ-opioid receptors readily form heterodimers 48 and that the δ-opioid receptors modulate the function of μ-opioid receptors in this complex. 49 Thus, our opioid derivatives displaying dual μ-/δ-agonism (7') and mixed μ-agonism/δ-antagonism (6', 4') characteristics which are shown to exhibit a low tendency to develop dependence and tolerance, 50 and verified using δ-receptor knockout mice 51 and a δ-receptor antagonist 52 might be applicable for antinociception with a low degree of dependence and tolerance. Furthermore, structural clarification of the subtle differences among these interrelated opioid ligands 14,23 should provide insight on the molecular mechanism of action between agonists and antagonists. 53
Experimental Section
Melting points were determined on a Yanagimoto micromelting point apparatus and are uncorrected. TLC was performed on precoated plates of silica gel F254 (Merk, Darmstadt, Germany The H-Phe-NH 2 hydrochloride salt (0.25 g, 1.25 mmol) was dissolved in DMF (N,Ndimethylformamide: 10 mL) containing DIPEA (diisopropylethylamine: 0.50 mL, 2.87 mmol), and to this solution Boc-Xaa-OH (1.14 mmol) and PyBop (0.65 g, 1.25 mmol) were added. The reaction mixture was stirred at 0 °C for 10 min, then room temperature for 4 h. After remove of solvent, the residue was diluted with AcOEt (80 mL). The dilution was washed with ice cooled 10% citric acid (3 × 15 mL), 5% Na 2 CO 3 (3 × 15 mL) and saturated NaCl (3 × 20 mL), dried over Na 2 SO 4 and evaporated to dryness. The residue was purified by flash chromatography (SiO 2 , AcOEt). The compound was precipitated with hexane, collected by filtration and dried under vacuum. Elemental analyses of Boc-Xaa-Phe-NH 2 are summarized in Supporting Information (Table 2) . Boc-Xaa-Phe-NH 2 (0.44 mmol) was treated with 7.7 mol/L HCl/dioxane (1.15 mL, 8.8 mmol) to remove the Boc group at room temperature for 30 minutes. The product was precipitated with ether, filtered and dried under vacuum. The resulted hydrochloride salt was dissolved in DMF (10 mL) containing DIPEA (184 µL, 1.06 mmol), and to this solution Boc-Xaa-Pro-OH (0.44 mmol) and PyBop (252 mg, 0.49 mmol) were added. The reaction mixture was stirred at 0 °C for 10 min, then room temperature for 4 h. After removal of solvent, the residue was diluted with AcOEt. The dilution was washed with ice cooled 10% citric acid (3 × 15 mL), 5% Na 2 CO 3 (3 × 15 mL) and saturated NaCl (3 × 20 mL), dried over Na 2 SO 4 and evaporated to dryness. The residue was purified by flash chromatography (SiO 2 , AcOEt:MeOH = 10:1). The compound was precipitated with hexane, filtered and dried under vacuum. Elemental analyses of Boc-Tyr/Dmt-Pro-Xaa-Phe-NH 2 are summarized in Supporting Information (Table 3) . 10 (m, 3.60H, Pro trans-αH, Imp αH, Tyr αH, Phe trans-αH), 3.90 (d, 0.19H Boc-Tyr/Dmt-Pro-Xaa-Phe-NH 2 (0.25 mmol) was treated with TFA (0.6 mL, 7.79 mmol) and anisole (40 µL) for 1 h at room temperature. The reaction solution was diluted with hexane, the solid was collected by filtration, dried over KOH pellets and purified by semi-preparative RP-HPLC. The purified peptide was lyophilized from water (3 × 10 mL) containing 1 mol/L HCl (0.25 mL, 0.25 mmol) to give amorphous powder. Elemental analyses of H-Tyr/Dmt-ProXaa-Phe-NH 2 are summarized in Supporting Information (Table 4) . Pro trans-γH), 1.59-1.44 (m, 0.68H, Pro cis-βH, Pro cis-γH), 1.44-1.32 (m, 0.34H , Pro cis-βH), 1.32-1.16 (m, 0.34H, Pro cis-γH). 13 2',6'-Dimethyl-L-tyrosylprolyl-2'-isopropyl-6'-methyl-L 
Tyrosylprolyl-2'-methyl-L-phenylalanylphenylalanylamide Hydrochloride (2)-
Opioid Receptor Binding Assays
Opioid receptor affinities were determined under equilibrium conditions [2.5 h at room temperature (22 °C)] in a competition assay using brain P 2 synaptosomal membranes prepared from 150-160 g Sprague-Dawley rats. 29,40 Synaptosomes were preincubated to remove endogenous opioids for 60 min at 22 °C, washed in excess ice-cold buffer (50 mM Tris-HCl, pH 7.5) containing protease inhibitor (soybean trypsin inhibitor) and stored in a 20% glycerolcontaining buffer (50 mM HEPES, pH 7.5) with protease inhibitor at −80 °C as described previously. 29,40 The δ-and μ-opioid receptors were radiolabeled with 1.9 nM established the level of nonspecific binding. After incubation, the radiolabeled membranes containing both radioligands were rapidly filtered on Whatman GF/C glass fiber filters presoaked in 0.1% polyetheneimine in order to optimize the signal-to-noise ratio, washed with ice-cold Tris-HCl-BSA (bovine serum albumin) buffer, and dried at 75-80 °C for 1 hr. Radioactivity was determined using EcoLume (ICN, Costa Mesa, CA). All compounds are analyzed in duplicate using 5-8 peptide dosages and several synaptosomal preparations in independent repetitions (n values noted in Table 2 
Biological Activity in Isolated Tissue Preparation
The myenteric plexus longitudinal muscle preparations (2-3 cm segments) from the small intestine of male Hartley strain guinea pigs (GPI) measured μ-opioid receptor agonism and a single mouse vas deferens (MVD) was used to determine δ-opioid receptor agonism as described previously. [33] [34] [35] The isolated tissues were suspended in organ baths containing balanced salt solutions in a physiological buffer, pH 7.5. Agonists were tested for the inhibition of electrically evoked contraction and expressed as IC 50 (nM) obtained from the dose-response curves. The IC 50 values represent the mean ± SE of five to six separate assays. δ-Opioid antagonist potencies in the MVD assay were determined against the δ agonist deltorphin-II and are expressed as pA 2 determined using the Schild Plot. 57 The Schild slopes of all analogues were 0.88-1.07. , respectively). Table 3 Functional Bioactivities of H-Tyr/Dmt-Pro-Xaa-Phe-NH c Negative log of the molar concentration required to double the deltorphin II concentration to achieve the original response. 
